A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FR α-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancer

CONCLUSION: MIRV and gemcitabine demonstrate promising activity in platinum resistant EOC at RP2D, but frequent hematologic toxicities.PMID:38262235 | DOI:10.1016/j.ygyno.2023.12.017

Source: Gynecologic Oncology - January 23, 2024 Category: Cancer & Oncology Authors: Mihaela C Cristea Daphne Stewart Timothy Synold Nora Ruel Joanne Mortimer Edward Wang Alexander Jung Sharon Wilczynski Gottfried E Konecny Melissa Eng Lindsay Kilpatrick Ernest Han Thanh Dellinger Amy Hakim Stephen Lee Robert J Morgan Mark T Wakabayashi P Source Type: research